{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:33:58Z","timestamp":1779219238820,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.xphs.2022.12.021","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T02:06:44Z","timestamp":1672020404000},"page":"893-903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Levocetirizine Dihydrochloride"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-1179","authenticated-orcid":false,"given":"Naseem A.","family":"Charoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daud B.","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoud T.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertil","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Cristofoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-3899","authenticated-orcid":false,"given":"Alan","family":"Parr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kambayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2022.12.021_bib0001","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1067\/mai.2002.121701","article-title":"Rhinitis as an independent risk factor for adult-onset asthma","volume":"109","author":"Guerra","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.xphs.2022.12.021_bib0002","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(08)61446-4","article-title":"Rhinitis and onset of asthma: a longitudinal population-based study","volume":"372","author":"Shaaban","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.021_bib0003","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision","volume":"140","author":"Bro\u017cek","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2022.12.021_bib0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1710-1492-5-14","article-title":"The anti-inflammatory effects of levocetirizine\u2013are they clinically relevant or just an interesting additional effect?","volume":"5","author":"Walsh","year":"2009","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.xphs.2022.12.021_bib0005","unstructured":"Summary of product characeristics. Levocetirizine 5 mg film-coated tablets. Available at:https:\/\/www.medicines.org.uk\/emc\/product\/9917#gref. (Accessed 13 October 2022)"},{"key":"10.1016\/j.xphs.2022.12.021_bib0006","unstructured":"U.S. Food and Drug Administration, Department of health and human services center for devices and radiological health. In: guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Silver Spring, MD: FDA; 2017. Available at:https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070246.pdf. (Accessed 13 October 2022)."},{"key":"10.1016\/j.xphs.2022.12.021_bib0007","unstructured":"European Medicines Agency (EMA), 2010. Guideline on the investigation of bioequivalence. Doc.Ref.:CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/Corr. Available at:https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. (Accessed 13 October 2022)."},{"key":"10.1016\/j.xphs.2022.12.021_bib0008","unstructured":"International Conference on Harmonization (ICH). Biopharmaceutics classification system-based biowaivers. M9, 2020. Available at:https:\/\/database.ich.org\/sites\/default\/files\/M9_Guideline_Step4_2019_1116.pdf (Accessed 23 October 2022)."},{"key":"10.1016\/j.xphs.2022.12.021_bib0009","series-title":"Expert Committee on Specifications for Pharmaceutical Preparations. Fifty -first report. World Health Organization technical report series","first-page":"1003","year":"2017"},{"issue":"1","key":"10.1016\/j.xphs.2022.12.021_bib0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.xphs.2021.09.031","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: sitagliptin phosphate monohydrate","volume":"111","author":"Charoo","year":"2022","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2022.12.021_bib0011","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.xphs.2020.06.007","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: moxifloxacin hydrochloride","volume":"109","author":"Charoo","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.021_bib0012","unstructured":"USP39NF. Levocetirizine dihydrochloride tablets. P4541."},{"key":"10.1016\/j.xphs.2022.12.021_bib0013","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1034\/j.1398-9995.2001.00726.x","article-title":"A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers","volume":"56","author":"Devalia","year":"2001","journal-title":"Allergy"},{"key":"10.1016\/j.xphs.2022.12.021_bib0014","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s002280100364","article-title":"Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers","volume":"57","author":"Benedetti","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2022.12.021_bib0015","unstructured":"Xyzal\u00ae. FDA, 1995. Highlights of prescribing information. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022064s009lbl.pdf. (Accessed 13 October 2022)."},{"issue":"6","key":"10.1016\/j.xphs.2022.12.021_bib0016","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jaci.2007.02.048","article-title":"Relevance of H1-receptor occupancy to H1-antihistamine dosing in children","volume":"119","author":"Simons","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.xphs.2022.12.021_bib0017","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00011-003-1193-5","article-title":"Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin","author":"Denham","year":"2003","journal-title":"Inflamm Res"},{"issue":"6","key":"10.1016\/j.xphs.2022.12.021_bib0018","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00011-006-0075-z","article-title":"A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo","volume":"55","author":"Popov","year":"2006","journal-title":"Inflamm Res"},{"key":"10.1016\/j.xphs.2022.12.021_bib0019","first-page":"113","article-title":"Nicolae Miron 4, Irena Pintea 2,3, Carmen Teodora Dobrican 2,3, Corina Ureche 5,*, Anca Dana Buzoianu 1 and Diana Deleanu. Are Markers of Allergic Inflammation in Grass Pollen Allergy Influenced by H1 Antihistamines","volume":"11","year":"2022","journal-title":"J. Clin. Med"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.021_bib0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000321181","article-title":"Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease","volume":"155","author":"Pampura","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"issue":"24","key":"10.1016\/j.xphs.2022.12.021_bib0021","first-page":"872","article-title":"The value of broad therapeutic index for antihistamines","volume":"2","author":"Simons","year":"2002","journal-title":"Adv Stud Med"},{"key":"10.1016\/j.xphs.2022.12.021_bib0022","unstructured":"FDA. 2022. Orange book: approved drug products with therapeutic equivalence evaluations. Available at:https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm. (Accessed 30 March 2022)."},{"key":"10.1016\/j.xphs.2022.12.021_bib0023","unstructured":"Public Assessment Report. Levocetirizine Substipharm 5 mg orodispersible tablet Evianzin 5 mg orodispersible tablet Loritozin 5 mg orodispersible tablet (Levocetirizine dihydrochloride) ES\/H\/0398\/001\/DC ES\/H\/0399\/001\/DC ES\/H\/0400\/001\/DC. Available at:https:\/\/cima.aemps.es\/cima\/pdfs\/ipe\/83352\/IPE_83352.pdf. (Accessed 13 October 2022)."},{"key":"10.1016\/j.xphs.2022.12.021_bib0024","unstructured":"USP39NF. Levocetirizine dihydrochloride. P4539."},{"key":"10.1016\/j.xphs.2022.12.021_bib0025","unstructured":"Xyzal. Levocetirizine dihydrochloride. Available at:https:\/\/www.rxlist.com\/xyzal-drug.htm#description. (Accessed 17 October 2022)."},{"key":"10.1016\/j.xphs.2022.12.021_bib0026","unstructured":"Reddy MS, Srinivasan TR, Uppala MB, Vaddadi PR, Joga R. 2003. Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof. WO2004050647A3, WIPO (PCT)"},{"key":"10.1016\/j.xphs.2022.12.021_bib0027","unstructured":"C\u00e9lal A, Emile C, Didier B. Piperazine derivatives and their use as synthesis intermediates. 2004. WO2004\/065360"},{"key":"10.1016\/j.xphs.2022.12.021_bib0028","unstructured":"Public Assessment Report. Levocetirizina IPCA. 5 mg film-coated tablets (Levocetirizine dihydrochloride). PT\/H\/0940\/001\/DC. Available at:https:\/\/mri.cts-mrp.eu\/Human\/Downloads\/PT_H_0940_001_FinalPI_1of5.pdf. (Accessed 13 October 2022)."},{"key":"10.1016\/j.xphs.2022.12.021_bib0029","unstructured":"FDA. 2007. Clinical pharmacology review. Levocetirizine dihydrochloride. NDA: 22-157. Available at:https:\/\/www.fda.gov\/media\/71515\/download. (Accessed 23 October 2022)."},{"key":"10.1016\/j.xphs.2022.12.021_bib0030","unstructured":"FDA, 2009. Clinical pharmacology and biopharmaceutics review(s). Zyrtec\u00ae (cetirizine HCl) Orally Disintegrating Tablets (10 mg). Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022578Orig1s000ClinPharmR.pdf. (Accessed 13 October 2022)."},{"issue":"4","key":"10.1016\/j.xphs.2022.12.021_bib0031","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1472-8206.2004.00254.x","article-title":"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans","volume":"8","author":"Molimard","year":"2004","journal-title":"Fndametal Clin Pharmacol"},{"key":"10.1016\/j.xphs.2022.12.021_bib0032","unstructured":"FDA, 2006. Clinical pharmacology and biopharmaceutics review. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022064s000_ClinPharmR.pdf. (Accessed 13 October 2022)."},{"issue":"1","key":"10.1016\/j.xphs.2022.12.021_bib0033","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/21556660.2014.928302","article-title":"Comparison of levocetirizine pharmacokinetics after single doses of levocetirizine oral solution and cetirizine dry syrup in healthy Japanese male subjects","volume":"3","author":"Ino","year":"2014","journal-title":"J Drug Assess"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.021_bib0034","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1472-8206.2001.00035.x","article-title":"Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers","volume":"15","author":"Baltes","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.021_bib0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2005.04.010","article-title":"Levocetirizine: Pharmacokinetics and pharmacodynamics in children age 6 to 11 years","volume":"116","author":"Simons","year":"2005","journal-title":"J Aller Clin Immunol"},{"key":"10.1016\/j.xphs.2022.12.021_bib0036","unstructured":"FDA 2009. Clinical Pharmacology Review. NDA: 22-064, S017 (pediatric supplement). Available at:https:\/\/www.fda.gov\/media\/77886\/download"},{"key":"10.1016\/j.xphs.2022.12.021_bib0037","unstructured":"PMDA. Zyzar Tablets 5mg Galaxosmithkline Co. Ltd. Available at:https:\/\/www.pmda.go.jp\/drugs\/2010\/P201000063\/34027800_22200AMX00949_I100_1.pdf. (Accessed 9 October 2022)."},{"key":"10.1016\/j.xphs.2022.12.021_bib0038","unstructured":"FDA, 2020. In Vitro drug interaction studies \u2014 cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. Available at:https:\/\/www.fda.gov\/media\/134582\/download. (Accessed 9 October 2022)."},{"issue":"7","key":"10.1016\/j.xphs.2022.12.021_bib0039","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/chir.20815","article-title":"Stereoselective and multiple carrier-mediated transport of cetirizine across Caco-2 cell monolayers with potential drug interaction","volume":"22","author":"He","year":"2010","journal-title":"Chirality"},{"issue":"9","key":"10.1016\/j.xphs.2022.12.021_bib0040","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.xphs.2017.03.026","article-title":"Cellular uptake of levocetirizine by organic anion transporter 4","volume":"106","author":"Noguchi","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.021_bib0041","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bjp.0707318","article-title":"Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig","volume":"151","author":"Gupta","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.xphs.2022.12.021_bib0042","unstructured":"FDA. 2008. Draft Guidance on Levocetirizine Dihydrochloride. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Levocetirizine%20Dihydrochloride_draft_Oral%20tab_RLD%2022064_RC10-08.pdf. (Accessed 13 October 2022)."},{"issue":"7","key":"10.1016\/j.xphs.2022.12.021_bib0043","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/cpdd.791","article-title":"Levocetirizine oral disintegrating tablet: a randomized open-label crossover bioequivalence study in healthy Japanese volunteers","volume":"9","author":"Ino","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.xphs.2022.12.021_bib0044","unstructured":"Public assessment report (PAR). Hexal AG. UK\/H\/2333\/01\/DC. Available at:https:\/\/www.geneesmiddeleninformatiebank.nl\/pars\/h102859.pdf. (Accessed 23 October 2022)."},{"issue":"1","key":"10.1016\/j.xphs.2022.12.021_bib0045","first-page":"149","article-title":"Randomized, double-blind, crossover comparison between two levocetirizine formulations on histamine-induced cutaneous response in healthy male human adult volunteers","volume":"5","author":"Usharani","year":"2005","journal-title":"J Appl Res"},{"key":"10.1016\/j.xphs.2022.12.021_bib0046","unstructured":"EMA, 2015. Final assessment report following the re-examination procedure. Referral under Article 31 of Directive 2001\/83\/EC Medicinal products for which the clinical part of bioequivalence studies has been carried out by GVK Biosciences Hyderabad during the time period 2004-2014 Procedure number: Available at: EMEA\/H\/A-31\/1408.https:\/\/www.ema.europa.eu\/en\/documents\/referral\/gvk-biosciences-article-31-referral-gvk-biosciences-final-assessment-report-following-re-examination_en.pdf. (Accessed 13 October 2022)."},{"issue":"3","key":"10.1016\/j.xphs.2022.12.021_bib0047","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jpba.2010.05.001","article-title":"Reaction between drug substances and pharmaceutical excipients: formation of esters between cetirizine and polyols","volume":"53","author":"Yu","year":"2010","journal-title":"J Pharm Biomed Anal"},{"issue":"18","key":"10.1016\/j.xphs.2022.12.021_bib0048","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1080\/10826076.2011.585485","article-title":"Optimization and validation of reverse phase liquid chromatographic method for estimation of cetirizine mannitol ester impurity in cetirizine hydrochloride chewable tablet","volume":"34","author":"Sharma","year":"2011","journal-title":"J Liq Chromatog Rel Technol"},{"key":"10.1016\/j.xphs.2022.12.021_bib0049","unstructured":"FDA. Dissolution testing and acceptance criteria for immediate-release solid oral dosage form drug products containing high solubility drug substances. 2018. Available at:https:\/\/www.fda.gov\/media\/92988\/download. (Accessed 7 September 2022)."},{"issue":"7","key":"10.1016\/j.xphs.2022.12.021_bib0050","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.xphs.2022.12.021_bib0051","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/0378-6323.58684","article-title":"Updosing of antihistamines to improve control of chronic urticaria","volume":"76","author":"Godse","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"10.1016\/j.xphs.2022.12.021_bib0052","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","article-title":"The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria","volume":"125","author":"Staevska","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.xphs.2022.12.021_bib0053","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/cea.13500","article-title":"Cardiac safety of second-generation H1-antihistamines when updosed in chronic spontaneous urticarial","volume":"49","author":"Cataldi","year":"2019","journal-title":"Clin Exper Allergy"},{"issue":"6","key":"10.1016\/j.xphs.2022.12.021_bib0054","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1399-3038.2007.00558.x","article-title":"Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: an 18-month study","volume":"18","author":"Simons","year":"2007","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.021_bib0055","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2500\/aap.2010.31.3349","article-title":"Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria","volume":"31","author":"Hampel","year":"2010","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.xphs.2022.12.021_bib0056","first-page":"12","article-title":"Suppression of osteopontin functions by levocetirizine, a histamine receptor antagonist, in vitro","author":"Komatsuzaki","year":"2013","journal-title":"BioMed Res Internat"},{"issue":"3","key":"10.1016\/j.xphs.2022.12.021_bib0057","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2340\/00015555-1490","article-title":"The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers","volume":"93","author":"Schoepke","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"13","key":"10.1016\/j.xphs.2022.12.021_bib0058","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.2147\/DDDT.S215316","article-title":"The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of levocetirizine dihydrochloride in healthy Chinese volunteers","volume":"18","author":"Cheng","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.xphs.2022.12.021_bib0059","first-page":"79","article-title":"Bioequivalence study of levocetirizine dihydrochloride 5 mg tablets in healthy thai male volunteers","volume":"11","author":"Teerawonganan","year":"2015","journal-title":"Isan J Pharmaceut Sci"},{"key":"10.1016\/j.xphs.2022.12.021_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.56808\/3027-7922.2067","article-title":"Pharmacokinetic and bioequivalence evaluation of two formulations of levocetirizine 5 mg in healthy Thai volunteers","volume":"37","author":"Jantarat","year":"2013","journal-title":"Thai J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2022.12.021_bib0061","unstructured":"Public assessment report. Levocetirizine dihydrochloride 5 mg film coated tablets. UK\/H\/2337\/01\/DC. Actavis. Available at:https:\/\/www.geneesmiddeleninformatiebank.nl\/pars\/h102860.pdf. (Accessed 13 October 2022)."}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922005846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922005846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:40:46Z","timestamp":1758361246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922005846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0022354922005846"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.12.021","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Levocetirizine Dihydrochloride","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}